相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1α and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro
Tomokazu Tanaka et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2017)
Hallmarks of cancer and AU-rich elements
Khalid S. A. Khabar
WILEY INTERDISCIPLINARY REVIEWS-RNA (2017)
Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue
Atreyi Dasgupta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Heart Disease and Stroke Statistics-2016 Update A Report From the American Heart Association
Dariush Mozaffarian et al.
CIRCULATION (2016)
Chemistry and biology of the compounds that modulate cell migration
Etsu Tashiro et al.
JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY (2016)
ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks
Qiancheng Shen et al.
NUCLEIC ACIDS RESEARCH (2016)
L744,832 and Everolimus Induce Cytotoxic and Cytostatic Effects in Non-Hodgkin Lymphoma Cells
Jose Mendes et al.
PATHOLOGY & ONCOLOGY RESEARCH (2016)
Latest Advances Towards Ras Inhibition: A Medicinal Chemistry Perspective
Brice Sautier et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Discovery and preliminary structure-activity relationship studies on tecomaquinone I and tectol as novel farnesyltransferase and plasmodial inhibitors
Melissa M. Cadelis et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
New indolizine-chalcones as potent inhibitors of human farnesyltransferase: Design, synthesis and biological evaluation
Iuliana-Monica Moise et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Shaoyong Lu et al.
CHEMICAL SOCIETY REVIEWS (2016)
Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome
Leslie B. Gordon et al.
CIRCULATION (2016)
Recent advances in cancer drug discovery targeting RAS
Candice Y. Wilson et al.
DRUG DISCOVERY TODAY (2016)
Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia
Yanan Gao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Ethan J. Brock et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)
Protein prenylation: unique fats make their mark on biology
Mei Wang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
The role of wild type RAS isoforms in cancer
Bingying Zhou et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)
A ntitumor effect of manumycin on colorectal cancer cells by increasing the reactive oxygen species production and blocking PI3K-AKT pathway
Jingyu Zhang et al.
ONCOTARGETS AND THERAPY (2016)
Protein Prenylation Constitutes an Endogenous Brake on Axonal Growth
Hai Li et al.
CELL REPORTS (2016)
Role of computer-aided drug design in modern drug discovery
Stephani Joy Y. Macalino et al.
ARCHIVES OF PHARMACAL RESEARCH (2015)
Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis
Fariborz Mortazavi et al.
BMC CANCER (2015)
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Adrienne D. Cox et al.
CLINICAL CANCER RESEARCH (2015)
A novel role of farnesylation in targeting a mitotic checkpoint protein, human Spindly, to kinetochores
Devinderjit K. Moudgil et al.
JOURNAL OF CELL BIOLOGY (2015)
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial
Christopher Koh et al.
LANCET INFECTIOUS DISEASES (2015)
The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents
Yan Shen et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2015)
Preventing farnesylation of the dynein adaptor Spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors
Andrew J. Holland et al.
MOLECULAR BIOLOGY OF THE CELL (2015)
Synthesis and biological evaluation of pentanedioic acid derivatives as farnesyltransferase inhibitors
Liuqing Yang et al.
MEDCHEMCOMM (2015)
Molecular Pathways: Targeting the Dependence of Mutant RAS Cancers on the DNA Damage Response
Elda Grabocka et al.
CLINICAL CANCER RESEARCH (2015)
Lonafarnib Is a Potential Inhibitor for Neovascularization
Linlin Sun et al.
PLOS ONE (2015)
Antroquinonol blocks Ras and Rho signaling via the inhibition of protein isoprenyltransferase activity in cancer cells
Ching-Liang Ho et al.
BIOMEDICINE & PHARMACOTHERAPY (2014)
Farnesyltransferase inhibitors: CAAX mimetics based on different biaryl scaffolds
Valentina Straniero et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Novel indolizine derivatives with unprecedented inhibitory activity on human farnesyltransferase
Carmen Dumea et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung Cancer
Neil Vasan et al.
CLINICAL CANCER RESEARCH (2014)
Dietary flavonoids fisetin and myricetin: Dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II
Huangtao Jin et al.
FITOTERAPIA (2014)
Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells
Husheng Ding et al.
HAEMATOLOGICA (2014)
Ras-induced Epigenetic Inactivation of the RRAD ( Ras-related Associated with Diabetes) Gene Promotes Glucose Uptake in a Human Ovarian Cancer Model
Yan Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia
K. C. Ray et al.
ONCOGENE (2014)
Transformation by HrasG12V is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition
X. Chen et al.
ONCOGENE (2014)
Farnesyltransferase Regulates Neutrophil Recruitment and Tissue Damage in Acute Pancreatitis
Mohammed Merza et al.
PANCREAS (2014)
Activation of the RhoB Signaling Pathway by Thyroid Hormone Receptor β in Thyroid Cancer Cells
Sayaka Ichijo et al.
PLOS ONE (2014)
FARNESYL TRANSFERASE INHIBITOR, TIPIFARNIB, PREVENTS GALACTOSAMINE/LIPOPOLYSACCHARIDE-INDUCED ACUTE LIVER FAILURE
Kazuhiro Shirozu et al.
SHOCK (2014)
The Structural Basis of ATP as an Allosteric Modulator
Shaoyong Lu et al.
PLOS COMPUTATIONAL BIOLOGY (2014)
Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice
Igor G. Nikolov et al.
ATHEROSCLEROSIS (2013)
Novel route to chaetomellic acid A and analogues: Serendipitous discovery of a more competent FTase inhibitor
Franco Bellesia et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Synthesis and biological evaluation of a new series of N-ylides as protein farnesyltransferase inhibitors
Cristina-Maria Abuhaie et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
N. S. H. N. Moorthy et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Effect of farnesyltransferase inhibition on cardiac remodeling in spontaneously hypertensive rats
Xia Li et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Novel derivatives of aclacinomycin A block cancer cell migration through inhibition of farnesyl transferase
Shigeyuki Magi et al.
JOURNAL OF ANTIBIOTICS (2013)
Farnesyltransferase Haplodeficiency Reduces Neuropathology and Rescues Cognitive Function in a Mouse Model of Alzheimer Disease
Shaowu Cheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis
Sebastien Lethu et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2013)
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
I. V. Fedorenko et al.
ONCOGENE (2013)
Discovery of novel inhibitors for human farnesyltransferase (hFTase) via structure-based virtual screening
Xiaojuan Yu et al.
MEDCHEMCOMM (2013)
Ras and Rheb Signaling in Survival and Cell Death
Anja Ehrkamp et al.
Cancers (2013)
Inhibition of farnesyltransferase reduces angiogenesis by interrupting endothelial cell migration
Guoyuan Peng et al.
BIOCHEMICAL PHARMACOLOGY (2012)
New farnesyltransferase inhibitors in the phenothiazine series
Dalila Belei et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Farnesyltransferase inhibitor induces p53-dependent cellular senescence in colon cancer cells
Limin Zhu et al.
CANCER RESEARCH (2012)
Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells
G. Pelaia et al.
CELL PROLIFERATION (2012)
Is there a future for prenyltransferase inhibitors in cancer therapy?
Sarah A. Holstein et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Lonafarnib for cancer and progeria
Nan Soon Wong et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Farnesyltransferase Inhibitor Manumycin Targets IL1β-Ras-HIF-1α Axis in Tumor Cells of Diverse Origin
Vivek Sharma et al.
INFLAMMATION (2012)
Phosphatase of regenerating liver-3 promotes migration and invasion by upregulating matrix metalloproteinases-7 in human colorectal cancer cells
Su-Kyung Lee et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer
Seung Hyun Oh et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Matrix metalloproteinase-1 contribution to sarcoma cell invasion
Nandor Garamszegi et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome
Leslie B. Gordon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Targeting the Tumor Microenvironment: Focus on Angiogenesis
Fengjuan Fan et al.
JOURNAL OF ONCOLOGY (2012)
Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase
Cristiano Bolchi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Synthesis and anti-migrative evaluation of moverastin derivatives
Masato Sawada et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Inhibition of Ras for cancer treatment: the search continues
Antonio T. Baines et al.
FUTURE MEDICINAL CHEMISTRY (2011)
FTI-277 INHIBITS VASCULAR CALCIFICATION BY ACTIVATING DOWNSTREAM PI3K/AKT SIGNALLING AND PREVENTING APOPTOSIS OF VASCULAR SMOOTH MUSCLE CELLS
A. Ponnusamy et al.
HEART (2011)
Autophagy as a therapeutic target in cardiovascular disease
Andriy Nemchenko et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2011)
Fast and effective identification of the bioactive compounds and their targets from medicinal plants via computational chemical biology approach
Shoude Zhang et al.
MEDCHEMCOMM (2011)
RAS oncogenes: weaving a tumorigenic web
Yuliya Pylayeva-Gupta et al.
NATURE REVIEWS CANCER (2011)
The Farnesyltransferase Inhibitor LB42708 Suppresses Vascular Endothelial Growth Factor-Induced Angiogenesis by Inhibiting Ras-dependent Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt Signal Pathways
Chun-Ki Kim et al.
MOLECULAR PHARMACOLOGY (2010)
Atherosclerosis in CKD: differences from the general population
Tilman B. Drueeke et al.
NATURE REVIEWS NEPHROLOGY (2010)
Oncogenic Ras-induced expression of cytokines: A new target of anti-cancer therapeutics
Brooke B. Ancrile et al.
MOLECULAR INTERVENTIONS (2008)
Farnesyltransferase inhibitor, manumycin A, prevents atherosclerosis development and reduces oxidative stress in apolipoprotein E-deficient mice
Michiko Sugita et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation
Shao H. Yang et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria
LG Fong et al.
SCIENCE (2006)
PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis
TG Bivona et al.
MOLECULAR CELL (2006)
Targeting Rho and Rho-kinase in the treatment of cardiovascular disease
K Budzyn et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2006)
Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition
MW Glynn et al.
HUMAN MOLECULAR GENETICS (2005)
Molecular requirements for epithelial-mesenchymal transition during tumor progression
MA Huber et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Hypoxia-inducible factor 1α and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer
JY Han et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Dynamic mechanism for the autophosphorylation of CheA histidine kinase: Molecular dynamics simulations
J Zhang et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2005)
Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors
MR Lackner et al.
CANCER CELL (2005)
Oncogenic Ras and its role in tumor cell invasion and metastasis
PM Campbell et al.
SEMINARS IN CANCER BIOLOGY (2004)
Integrin signalling during tumour progression
WJ Guo et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-κB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-κB-regulated gene expression and up-regulation of apoptosis
Y Takada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis
A Sparmann et al.
CANCER CELL (2004)
Hutchinson-Gilford progeria syndrome
RL Pollex et al.
CLINICAL GENETICS (2004)
Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis
S Grünert et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome
M Eriksson et al.
NATURE (2003)
Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines
A Mazzocca et al.
MOLECULAR PHARMACOLOGY (2003)
uPAR: A versatile signalling orchestrator
F Blasi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
A prenylation inhibitor prevents production of infectious hepatitis delta virus particles
BB Bordier et al.
JOURNAL OF VIROLOGY (2002)
Ras farnesylation inhibitor FTI-277 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis
JS Nam et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells
S Le Gouill et al.
LEUKEMIA (2002)
Hypoxic induction of the hypoxia-inducible factor is mediated via the adaptor protein Shc in endothelial cells
F Jung et al.
CIRCULATION RESEARCH (2002)
Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis
CE Walters et al.
JOURNAL OF IMMUNOLOGY (2002)
Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth
J Lawler
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2002)
Fibronectin, integrins, and growth control
EHJ Danen et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2001)
Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis
MS Pepper
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
K Jiang et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
